Sleeping Bruxism Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Sleeping Bruxism Treatment Market Trends and Insights

Rising Diagnosis of Sleep Bruxism with OSA Overlap

The convergence of bruxism and OSA diagnosis inside multidisciplinary sleep workflows is changing how patients enter the sleep bruxism treatment market. Polysomnography data from 345 OSA patients showed that 13.6% had concurrent sleep bruxism, and this subgroup also had higher daytime sleepiness and reduced REM sleep. A separate study of 105 OSA patients found sleep bruxism in 37.1% of cases, and EMG-measured muscle tone produced an AUC of 0.9, which supports the use of wearable EMG for co-screening in sleep settings.^{[1]Janine Sambale, “Occlusion, Jaw Function and Nocturnal Muscle Tone in Obstructive Sleep Apnea With and Without Sleep Bruxism,” Clinical Oral Investigations, doi.org.} This matters commercially because co-diagnosed patients are more likely to move toward dual-use mandibular advancement devices or combined treatment plans instead of single-condition night guards. The literature is also increasingly anchored to AASM-linked diagnostic framing, which suggests sleep medicine standards will continue to shape prescriber behavior in the sleep bruxism treatment market, especially in North America. As these care pathways widen, providers that can address both airway management and tooth protection are likely to capture more of the sleep bruxism treatment market.

Shift Toward Custom Oral Appliances and Digital Dentistry

Digital fabrication is changing the cost, speed, and delivery model of custom oral appliances across the sleep bruxism treatment market. CAD/CAM milling, intraoral scanning, and additive manufacturing are shortening turnaround times and making remote fulfillment models more viable than before.^{[2]Ravinder S. Saini, “Comparison of Digital Splints Versus Traditional Splints for Bruxism Management, A Systematic Review,” BDJ Open, doi.org.} SomnoMed reported that manufacturing investments through 2025 reduced production turnaround from more than 20 days to under 10 days and expanded capacity by more than 40%, which strengthened its ability to convert users from competing products. Panthera’s digitally manufactured nylon appliances carry FDA 510(k) clearance, CE marking, and HCPCS billing support, which improves reimbursement fit and broadens their commercial reach beyond fully self-pay patients. A 2026 systematic review found that digital splints tended to reduce symptom severity more than conventional acrylic splints, although the trials were still limited in size. The result is a sleep bruxism treatment market that is becoming less dependent on the older multi-visit workflow and more responsive to faster custom production.

Adult Stress and Anxiety Burden Sustaining Treatment Demand

Stress and anxiety continue to support demand across the sleep bruxism treatment market, especially in adult and working-age populations. A cross-sectional study of 111 health science students found that 55.4% of bruxers had clinically relevant anxiety, and the rate was 2.8 times higher than in non-bruxers. A 12-month study of 136 dental students found that awake bruxism behaviors increased significantly over time, and each unit rise in perceived stress score raised the odds of bruxism behavior by 16% in the later phase.^{[3]Alona Emodi-Perlman, “Impact of Long-Term Stress on Awake Bruxism,” Dental and Medical Problems, dmp.umw.edu.pl.} These findings support the view that treatment demand is tied to persistent psychological burden rather than only short-lived episodes. That pattern gives providers and manufacturers a more durable demand base across the sleep bruxism treatment market, even when economic conditions improve. It also helps explain why multimodal protocols that combine physical protection with behavior-focused care are gaining traction.

Smart Oral Appliances and Biofeedback Moving into Premium Care

Biofeedback is moving from the research stage into premium care pathways within the sleep bruxism treatment market. Aesyra’s clinical investigation in 26 adults showed a 60.6% reduction in total sleep bruxism duration per hour, with no adverse events and positive comfort feedback. The company began its FDA submission in early 2026 and plans European regulatory filing after that, which points to near-term commercial readiness. An AI-enabled intraoral biofeedback prototype also achieved 91% accuracy and 90% specificity in distinguishing pathological occlusal force events after training on more than 50,000 data points. The clinical direction suggests that biofeedback may work best when paired with occlusal protection, especially in patients who need both activity reduction and protection from tooth wear. This keeps the premium end of the sleep bruxism treatment market focused on combined functionality rather than on simple substitution.

Underdiagnosis and No Universally Accepted Care Standard

The absence of a universally adopted clinical protocol continues to limit diagnosis and consistent treatment across the sleep bruxism treatment market. An overview of 31 systematic reviews concluded that the evidence base for oral appliances, pharmacological options, and biofeedback remained too heterogeneous to define a clear standard of care. That fragmentation means the same patient can receive different labels and different therapy recommendations depending on whether the first visit is with a general dentist, a sleep physician, or an orofacial pain specialist. Polysomnography remains the gold standard for definitive diagnosis, but cost and access still confine it to specialist settings, so many patients are managed under possible or probable bruxism categories rather than confirmed diagnosis. Reference systems such as ICSD-3 and AASM provide a useful framework, but routine use outside specialist practice remains limited. This slows patient conversion, weakens treatment consistency, and keeps part of the sleep bruxism treatment market below its epidemiological potential.

High Out-of-Pocket Costs and Patchy Reimbursement

Patient costs and uneven reimbursement continue to limit conversion to higher-value therapies in the sleep bruxism treatment market. Kaiser Permanente’s 2025 dental plan covers removable bruxism appliances at 35% coinsurance and limits replacement to once every 5 years, while HMSA excludes bite guards entirely. Blue Shield of California reimburses custom hard occlusal guards at USD 113 per appliance, which leaves a meaningful gap against normal clinical fabrication costs. Low reimbursement ceilings and replacement limits raise multi-year out-of-pocket exposure for patients who need ongoing appliance management. That cost burden pushes some patients toward OTC guards instead of clinician-guided custom care. It also narrows the addressable base for premium products and makes price sensitivity a persistent check on growth in the sleep bruxism treatment market.

Segment Analysis

By Treatment Modality: Behavioral Therapies Outpace Legacy Appliance Volumes

Dental appliances held 42.68% of treatment modality revenue in 2025, which kept them at the center of the sleep bruxism treatment market. Custom-fitted night guards, Michigan splints, and mandibular advancement devices remain the core products because they align with familiar first-line practice patterns in established dental systems. Their lead also reflects the established laboratory supply chain that manufactures and distributes these products at scale across clinic networks. Behavioral and physical therapy is projected to grow at an 8.22% CAGR through 2031, making it the fastest-rising treatment approach in the sleep bruxism treatment market. That growth reflects a broader shift toward non-invasive care that can reduce symptom burden without introducing a device-wear barrier for every patient. The sleep bruxism treatment industry is therefore moving toward a more balanced mix of protection, habit management, and supportive care.

The IAPD’s 2024 consensus on pediatric bruxism supports CBT and proprioceptive approaches when psychosocial factors are present, and that position is starting to influence wider protocol design. Pharmacological and injectable therapy remains relevant for patients with masseteric hypertrophy or TMD comorbidity, but the role of botulinum toxin in reducing episode frequency is still debated. A 2024 systematic review of 9 randomized trials found that botulinum toxin improved pain and EMG activity over the first 3 to 16 weeks, but the benefit weakened by 3.5 months. Device-assisted monitoring and biofeedback remain early in commercialization, yet clinical validation is giving that segment a clearer position inside the sleep bruxism treatment industry. Combination therapy is also drawing more interest in premium care settings where patients are willing to pay for broader protocols that unite protection, retraining, and monitoring.

By Product Type: Smart Devices Reframe the Night Guard Category

Mouth guards accounted for 45.17% of the sleep bruxism treatment market size in 2025, which made them the largest product category. Soft, hard, and dual-laminate designs remain widely used because they are familiar to prescribers and can be produced across major dental laboratory networks. Hard acrylic Michigan-style guards and flat-plane stabilization splints continue to dominate prescribed use because they provide durable occlusal protection across repeated wear cycles. Dual-laminate and hybrid designs are gaining attention because they try to combine durability with better comfort, and that directly addresses a common adherence barrier. In a German multicenter study, respiratory impairment from a splint reduced adherence by a factor of 10 after insertion, which shows how directly product comfort affects actual use.

Smart and biofeedback devices are projected to grow at a 7.92% CAGR through 2031, making them the fastest-growing product segment in the sleep bruxism treatment market. Their growth reflects the spread of sensor-based monitoring and the appeal of products that do more than passively shield teeth. Sensor-embedded intraoral devices and wearable EMG systems are moving treatment toward measurement, feedback, and remote follow-up rather than simple protection alone. This is one reason the sleep bruxism treatment market is seeing more premium product development, even while conventional guards still dominate volumes. Injectable and oral drug products still serve patients with poor appliance adherence or distinct pain-related needs, but they add incremental revenue rather than replacing appliance-led care across the sleep bruxism treatment market.

By Patient Type: Pediatric Diagnosis Driving a Latent Demand Wave

Adults represented 68.48% of revenue in 2025, which made them the main diagnosed and treated population in the sleep bruxism treatment market. Working-age and older adults account for most current demand because stress-related presentations and OSA-linked bruxism are more visible in these groups. Middle-aged adults are especially important commercially because they are the most active users of custom appliances and adjunctive therapies. Older adults are also becoming more relevant as restorative and prosthetic complications create additional reasons to seek treatment. This adult base keeps present revenue concentrated even as other patient groups expand.

Pediatric treatment is projected to grow at an 8.84% CAGR through 2031, which makes it the fastest-growing patient category in the sleep bruxism treatment market. A 2024 meta-analysis reported sleep bruxism prevalence of 28% in North American minors, 24% in South American minors, and 14.4% in Asian minors, which shows that the addressable population is larger than current treatment volumes imply. The IAPD’s 2024 recommendations also noted that prevalence reached 90.9% among children with tonsil hypertrophy, restricted tongue mobility, or nasal obstruction, linking airway issues to treatment need. This is pushing more attention toward earlier recognition by pediatric dentists and general practitioners. As recognition improves, the sleep bruxism treatment market is likely to convert more latent pediatric demand into active monitoring and treatment.

By End User: Home Care Models Disrupting Dental Clinic Primacy

Dental clinics held 57.35% of end-user revenue in 2025, which kept them as the leading access point in the sleep bruxism treatment market. Their position comes from their central role in prescribing and dispensing custom-fitted appliances and injection-based therapies. Close commercial ties between clinics and dental laboratories also support recurring appliance orders when devices need replacement or adjustment. Hospitals and multidisciplinary sleep centers form the next important tier, and their role is rising as more diagnoses flow through polysomnography-based sleep workflows. That shift means treatment decisions are increasingly shaped by sleep physicians as well as by dentists.

Home care settings are projected to grow at 10.01% CAGR through 2031, which gives them the highest growth rate among end users in the sleep bruxism treatment market. Direct-to-consumer custom guard platforms, at-home impression kits, and scan-based remote delivery are the main reasons this channel is expanding so quickly. Specialty sleep and neurology centers are also emerging as prescribing points for smart appliances and biofeedback devices in higher-severity cases. As care moves closer to the home, regulatory and reimbursement frameworks for prescription appliances and connected biofeedback devices become more important to what can be marketed and paid for. This is gradually redistributing value within the sleep bruxism treatment market from the clinic-only model toward hybrid care delivery.

Geography Analysis

North America held 37.24% of the sleep bruxism treatment market share in 2025, making it the largest regional segment. The region benefits from relatively strong dental insurance access, broad custom appliance use, and active work on dual-use OSA and bruxism solutions. The United States anchors most regional revenue because it combines a large dental channel with a more developed sleep medicine ecosystem. Diagnosis is also shifting toward multidisciplinary sleep settings, which increases the role of sleep laboratories and sleep physicians in therapy selection. That mix keeps North America commercially mature while still leaving room for premium device innovation and home-based care expansion.

Asia-Pacific is projected to expand at a 9.16% CAGR through 2031, giving it the fastest regional growth within the sleep bruxism treatment market size. Growth across the region is uneven, with Australia contributing more than 80% of SomnoMed’s APAC revenue while also facing competitive and economic pressure in the first half of FY26. China, Japan, and India remain underpenetrated markets where diagnosis is still limited or treatment remains conservative. That leaves a large untreated patient pool across the broader sleep bruxism treatment market. Rising dental infrastructure and consumer health spending continue to support the region’s forward growth path.

Europe remains the second-largest regional segment, and SomnoMed reported 17% revenue growth in Europe to AUD 32.7 million (USD 21.3 million) in the first half of FY26 as reimbursement expanded in France, Sweden, Germany, Norway, and Finland. Germany stands out as a notable demand center because the market combines meaningful patient volume with structured reimbursement and billing channels. The Middle East, Africa, and South America remain smaller today, but both regions are developing gradually as dental infrastructure and awareness improve. Brazil’s clinical research activity and the GCC’s ongoing dental investment support future entry opportunities for premium appliance suppliers. These regions still face cost constraints, which keep treated volumes below the level suggested by underlying epidemiology.